» Articles » PMID: 31789672

Host-vaginal Microbiota Interactions in the Pathogenesis of Bacterial Vaginosis

Overview
Date 2019 Dec 3
PMID 31789672
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: The cause of bacterial vaginosis, the most common cause of vaginal discharge in women, remains controversial. We recently published an updated conceptual model on bacterial vaginosis pathogenesis, focusing on the roles of Gardnerella vaginalis and Prevotella bivia as early colonizers and Atopobium vaginae and other bacterial vaginosis-associated bacteria (BVAB) as secondary colonizers in this infection. In this article, we extend the description of our model to include a discussion on the role of host-vaginal microbiota interactions in bacterial vaginosis pathogenesis.

Recent Findings: Although G. vaginalis and P. bivia are highly abundant in women with bacterial vaginosis, neither induce a robust inflammatory response from vaginal epithelial cells. These early colonizers may be evading the immune system while establishing the bacterial vaginosis biofilm. Secondary colonizers, including A. vaginae, Sneathia spp., and potentially other BVAB are more potent stimulators of the host-immune response to bacterial vaginosis and likely contribute to its signs and symptoms as well as its adverse outcomes.

Summary: Elucidating the cause of bacterial vaginosis has important implications for diagnosis and treatment. Our current bacterial vaginosis pathogenesis model provides a framework for key elements that should be considered when designing and testing novel bacterial vaginosis diagnostics and therapeutics.

Citing Articles

The Vaginal Virome in Women's Health and Disease.

Orton K, Monaco C Microorganisms. 2025; 13(2).

PMID: 40005796 PMC: 11858017. DOI: 10.3390/microorganisms13020431.


Cannabidiol (CBD) Acts as an Antioxidant on , Resulting in Reduced Metabolic Activity, Loss of Survivability, and Elimination of Biofilms.

Sionov R, Korem M, Polacheck I, Steinberg D Antibiotics (Basel). 2025; 14(2).

PMID: 40001381 PMC: 11851883. DOI: 10.3390/antibiotics14020136.


Disclosing α-lactalbumin impact on the intestinal and vaginal microbiota of women suffering from polycystic ovary syndrome.

Alessandri G, Mancabelli L, Fontana F, Lepore E, Forte G, Burratti M Microb Biotechnol. 2024; 17(10):e14540.

PMID: 39364592 PMC: 11450379. DOI: 10.1111/1751-7915.14540.


Exploring Oral and Vaginal Probiotic Solutions for Women's Health from Puberty to Menopause: A Narrative Review.

Romeo M, DUrso F, Ciccarese G, Di Gaudio F, Broccolo F Microorganisms. 2024; 12(8).

PMID: 39203456 PMC: 11356851. DOI: 10.3390/microorganisms12081614.


Viewing Native American Cervical Cancer Disparities through the Lens of the Vaginal Microbiome: A Pilot Study.

Laniewski P, Joe T, Jimenez N, Eddie T, Bordeaux S, Quiroz V Cancer Prev Res (Phila). 2024; 17(11):525-538.

PMID: 39172513 PMC: 11532753. DOI: 10.1158/1940-6207.CAPR-24-0286.


References
1.
Ramsey P, Lyon M, Goepfert A, Cliver S, Schwebke J, Andrews W . Use of vaginal polymorphonuclear to epithelial cell ratios for the prediction of preterm birth. Obstet Gynecol. 2004; 105(1):139-44. DOI: 10.1097/01.AOG.0000148269.36622.0a. View

2.
Castro J, Machado D, Cerca N . Unveiling the role of Gardnerella vaginalis in polymicrobial Bacterial Vaginosis biofilms: the impact of other vaginal pathogens living as neighbors. ISME J. 2019; 13(5):1306-1317. PMC: 6474217. DOI: 10.1038/s41396-018-0337-0. View

3.
Geisler W, Yu S, Venglarik M, Schwebke J . Vaginal leucocyte counts in women with bacterial vaginosis: relation to vaginal and cervical infections. Sex Transm Infect. 2004; 80(5):401-5. PMC: 1744893. DOI: 10.1136/sti.2003.009134. View

4.
Laniewski P, Cui H, Roe D, Barnes D, Goulder A, Monk B . Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis. Sci Rep. 2019; 9(1):7333. PMC: 6517407. DOI: 10.1038/s41598-019-43849-5. View

5.
Marrazzo J, Dombrowski J, Wierzbicki M, Perlowski C, Pontius A, Dithmer D . Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. Clin Infect Dis. 2018; 68(5):803-809. PMC: 6376090. DOI: 10.1093/cid/ciy554. View